Notice of extraordinary general meeting of Cell Impact

The shareholders of Cell Impact AB (Nasdaq First North GM: CI B), reg. no. 556576-6655, are hereby invited to participate in an extraordinary general meeting on Monday 9 August 2021.

Since the board's proposal on authorizing the board of directors to resolve upon issue of shares, warrants and/or convertibles was rejected by the annual general meeting the board has, in consultation with major shareholders, made a revised proposal for authorization of the board of directors to resolve upon issue of shares, warrants and/or convertibles and therefore convenes an extraordinary general meeting on Monday 9 August 2021. The revised proposal is somewhat narrower than the original proposal but still gives the board sufficient flexibility to resolve upon any capital raisings to secure financing of the company's business plan.

Due to the Covid-19 pandemic, the board of directors has decided that the extraordinary general meeting shall be conducted without physical attendance and that shareholders shall have the opportunity to exercise their voting rights only by voting in advance (postal voting) in accordance with the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations (Sw. Lagen (2020:198) om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor).

The company welcomes all shareholders to exercise their voting rights at the general meeting by voting in advance (postal voting) in accordance with the instructions below. Information about the resolutions made at the general meeting will be published on Monday 9 August 2021 as soon as the outcome of the voting is finally compiled.

Registration and notification

Shareholders who wish to attend the extraordinary general meeting:

  • must be recorded in the share register maintained by Euroclear Sweden AB on Friday 30 July 2021; and
  • must notify the company of their attendance no later than on Friday 6 August 2021 by voting in accordance with the instructions under the heading "Postal voting" below.

Shares registered in the name of a custodian

Shareholders whose shares are registered in the name of a custodian must temporarily have their shares re-registered in their own names in order to have the right to attend the general meeting. Shareholders must therefore, well in advance, contact the custodian in accordance with the custodian's routines and request such re-registration. A re-registration of shares made by the custodian no later than Tuesday 3 August 2021 will be taken into account when procuring the share register.

Postal voting

The board of directors has decided that shareholders shall be able to exercise their voting rights only by postal voting in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations (Sw. Lagen (2020:198) om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor). A special form must be used for postal voting. Preferably, a digital form must be used which will be available on the company's website www.cellimpact.com no later than Monday 19 July 2021, whereby the postal voting is made digitally using BankID or other identification method. For shareholders who do not wish to vote digitally, a physical form for postal voting will also be available at the company's address Källmossvägen 7A, Karlskoga and for printing on the company's website www.cellimpact.com no later than Monday 19 July 2021. This form is sent, completed and signed, by post to the company at the address Cell Impact AB (publ), att. Stefan Axellie, Källmossvägen 7A, 691 52 Karlskoga.

No separate notification is required as the submitted postal voting form is regarded as a notification. The complete postal voting form must be submitted to the company (digitally or by post) no later than Friday 6 August 2021.

The shareholders may, in the postal voting form, request that resolutions in one or more of the matters in the proposed agenda is to be postponed to a so-called continued general meeting, which may not be a held as a postal voting meeting only. Such a continued general meeting shall take place if the extraordinary general meeting so resolves or if owners of at least one tenth of all the shares in the company so request.

Proxies

Shareholders voting by proxy must issue a dated and signed power of attorney which is to be attached to the digital postal voting form together with a registration certificate or any other authorization documents for owners that are legal persons. A proxy form is available on the company's website www.cellimpact.com.

Shareholders' rights to receive information

At the extraordinary general meeting the shareholders have the right to, if the board of directors considers that this can be done without significant damage to the company, receive information about any circumstances that may affect the assessment of a matter in the agenda (i.e., the right stated in Chapter 7 Sections 32 and 57 of the Swedish Companies Act). Requests for such information must be submitted in writing to the company's address Cell Impact AB (publ), att. Stefan Axellie, Källmossvägen 7A, 691 52 Karlskoga or via e-mail to [email protected] and must be submitted to the company no later than ten days before the extraordinary general meeting, i.e. no later than Friday 30 July 2021.

The information will be made available on the company's website www.cellimpact.com no later than Wednesday 4 August 2021. The information will also be available at the company's office at Källmossvägen 7A in Karlskoga from the same day. The information will also be sent to the shareholder who requested it and who has provided its address.

Shares and votes

At the time of this notice, the total number of shares and votes in the company amount to the following. The total number of class A shares is 217,800 with a voting value of 1, corresponding to 217,800 votes, and the total number of class B shares is 58,624,534 with a voting value of 1/10, corresponding to 5,862,453.4 votes. Thus, there are a total of 58,842,334 shares and a total number of 6,080,253.4 votes in the company.

Proposed agenda for the meeting

  1. Opening of the extraordinary general meeting
  2. Election of the chairman of the extraordinary general meeting
  3. Election of one or two persons to check the minutes
  4. Preparation and approval of the voting list
  5. Approval of the agenda
  6. Determination of whether the extraordinary general meeting has been duly convened
  7. Decision on authorizing the board of directors to resolve upon issue of shares, warrants and/or convertibles
  8. Closing of the extraordinary general meeting

Section 2, election of the chairman of the extraordinary general meeting

The board proposes that lawyer Anna-Maria Heidmark Green at Advokatfirman Wåhlin AB is elected as chairman of the extraordinary general meeting, or in the event of her absence, the person appointed by the nomination committee.

Section 3, election of one or two persons to check the minutes

The board of directors proposes that Mattias Klintemar is appointed, together with the chairman, to check the minutes, or in the event of his absence, the person appointed by the nomination committee. The assignment to check the minutes also includes reviewing the voting list and that the received postal votes are correctly stated in the minutes of the meeting.

Section 4, preparation and approval of the voting list

The voting list proposed to be approved is the voting list that has been drawn up based on the general meeting share register and received postal votes and that has been approved by the chairman of the meeting and reviewed by the attestant.

Section 7, decision on authorizing the board of directors to resolve upon issue of shares, warrants and/or convertibles

The board proposes that the general meeting authorizes the board to, until the next annual general meeting and within the limits of the articles of association and on one or more occasions and with or without deviation from the shareholders' preferential rights, resolve upon issues of shares, warrants, and/or convertibles, provided that such issues may not entail an increase of the company's share capital by more than 20 percent, calculated on the size of the share capital the first time the authorization is used. Issues may be made against cash payment, issue in kind and/or set-off, or otherwise be combined with conditions. Issues shall be made in order to increase the production capacity and prepare the organization to enable future growth. Should the board of directors resolve on an issue of shares with deviation from the shareholders' preferential rights, the issue of share shall be made at market terms and conditions.

Furthermore, the board proposes that the board, or the person appointed by the board, shall have the right to make minor changes to the general meeting's decision which may be required in connection with registration with the Swedish Companies Registration Office or for other administrative reasons.

Special majority requirements

A decision in accordance with the board's proposals in Section 7 requires that is supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the extraordinary general meeting.

Processing of personal data

Cell Impact AB (publ), reg.no 556576-6655, registered in Karlskoga, is the controller of the processing of personal data performed by the company or its service providers in connection with the extraordinary general meeting. For information on how personal data is processed, please see

www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

For more information, please contact:

Mr. Pär Teike, CEO, +46 73-024 06 84 or [email protected].

About Cell Impact

Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique method for high-velocity forming, Cell Impact Forming, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.

The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company's Certified Advisor (CA). Contact info: +46 8-528 00 399 or [email protected].

Styrelsen i Cell Impact har beslutat om en fullt garanterad företrädesemission om upp till cirka 349 miljoner kronor

Styrelsen i Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" eller "Bolaget") har idag, med stöd av bemyndigandet lämnat av extra bolagstämma den 16 november 2021, beslutat om en fullt garanterad företrädesemission om högst 16 812 094 B-aktier med företrädesrätt för Bolagets befintliga aktieägare ("Företrädesemissionen"). Teckningskursen i Företrädesemissionen är 20,75 kronor per B-aktie. Om Företrädesemissionen fulltecknas kommer Bolaget tillföras cirka 349 miljoner kronor före avdrag för transaktionskostnader relaterade till Företrädesemissionen.


The Board of Directors in Cell Impact has resolved on a fully guaranteed rights issue of up to approximately SEK 349 million

The Board of Directors in Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") has today, pursuant to the authorization granted by the extra general meeting on November 16, 2021, resolved on a fully guaranteed rights issue of up to 16,812,094 series B shares with preferential right for the Company's existing shareholders (the "Rights Issue"). The subscription price in the Rights Issue is SEK 20.75 per series B share. If the Rights Issue is fully subscribed, the Company will receive approximately SEK 349 million before deduction of transaction costs related to the Rights Issue.


Uppdaterad indikativ tidplan för Cell Impacts fullt garanterade företrädesemission

Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" eller "Bolaget") meddelar idag en uppdaterad indikativ tidplan för den fullt garanterade Företrädesemissionen. Den uppdaterade indikativa tidplanen avviker från den tidigare kommunicerade indikativa tidplanen då planerat prospektgodkännande har senarelagts på grund av hög arbetsbelastning hos Finansinspektionens prospektenhet.


Updated indicative timetable for Cell Impact's fully guaranteed rights issue

Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") today announces an updated indicative timetable for the fully guaranteed Rights Issue. The updated indicative timetable deviates from the previously communicated indicative timetable due to a postponed prospectus approval as a result of high workload for the Swedish Financial Supervisory Authority's prospectus unit.


Kommuniké från extra bolagsstämma i Cell Impact

Extra bolagstämma i Cell Impact AB (publ) hölls den 16 november 2021 varvid aktieägarna bland annat fattade beslut om emissionsbemyndigande.


Extraordinary general meeting of Cell Impact

An extraordinary general meeting of Cell Impact AB (publ) was held on 16 November 2021 whereby the shareholders, inter alia, authorized the board of directors to resolve upon issue of shares, warrants and/or convertibles.


Kallelse till extra bolagsstämma i Cell Impact

Aktieägarna i Cell Impact AB (publ), org.nr 556576-6655, kallas härmed till extra bolagsstämma tisdagen den 16 november 2021.


Notice of extraordinary general meeting of Cell Impact

The shareholders of Cell Impact AB (publ), reg. no. 556576-6655, are hereby invited to participate in an extraordinary general meeting on Tuesday 16 November 2021.


Styrelsen i Cell Impact avser att besluta om en fullt garanterad företrädesemission om upp till cirka 350 miljoner kronor

Styrelsen i Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" eller "Bolaget") meddelar idag sin avsikt att besluta om en fullt garanterad företrädesemission av B-aktier om upp till cirka 350 miljoner kronor ("Företrädesemissionen"). En extra bolagsstämma föreslås besluta om ett emissionsbemyndigande, med stöd av vilket Bolagets styrelse avser att besluta om Företrädesemissionen. Bolagets extra bolagsstämma planeras att hållas den 16 november 2021 och kallelsen kommer att publiceras genom ett separat pressmeddelande. Syftet med Företrädesemissionen är att säkerställa fortsatt finansiering av Cell Impacts affärsplan med tillhörande ökning av Bolagets produktionskapacitet. Tillsammans med befintlig kassa förväntas nettolikviden från Företrädesemissionen vara tillräcklig för att finansiera Bolagets affärsplan till mitten av 2023 förutsatt att Företrädesemissionen inbringar en bruttolikvid om cirka 350 miljoner kronor.


The Board of Directors in Cell Impact intends to resolve on a fully guaranteed rights issue of up to approximately SEK 350 million

The Board of Directors in Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") today announces its intention to resolve on a fully guaranteed rights issue of series B shares of up to approximately SEK 350 million (the "Rights Issue"). An Extra General Meeting is proposed to authorize the Board of Directors to resolve on the Rights Issue. The Extra General Meeting intends to be held on November 16, 2021 and the notice will be announced through a separate press release. The purpose of the Rights Issue is to ensure continued financing of Cell Impact's business plan, which includes increasing the Company's production capacity. Together with existing cash, the net proceeds from the Rights Issue is expected to be sufficient to finance the Company's business plan to mid-2023 provided that the Rights Issue generates gross proceeds of approximately SEK 350 million.


Cell Impact delårsrapport för tredje kvartalet: Fortsatt stark tillväxt

Cell Impact AB (Nasdaq First North GM: CI B) lämnar följande finansiella sammanfattning för tredje kvartalet.


Cell Impact reports third quarter results: Continued strong growth

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the third quarter.




Cell Impact förstärker ledningen med ny HR-chef

Cell Impact AB (Nasdaq First North GM: CI B) meddelar att Karina Sick Larsson har utsetts till Chief Human Resources Officer (CHRO) med tillträdesdag 16 september 2021. Karina kommer ansvara för bolagets HR-funktion med fokus kompetensutveckling.


Cell Impact strengthens management with new CHRO

Cell Impact AB (Nasdaq First North GM: Cell Impact AB (Nasdaq First North GM: CI B) is pleased to announce that Karina Sick Larsson has been appointed as Chief Human Resources Officer (CHRO) and will start her position on September 16, 2021. Karina will be responsible for the company's human resources function with a focus on organizational development.


Cell Impact delårsrapport för andra kvartalet 2021: Stark tillväxt

Cell Impact AB (Nasdaq First North GM: CI B) lämnar följande finansiella sammanfattning för första kvartalet.


Cell Impact reports second quarter results for 2021: Strong growth

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.


Kommuniké från extra bolagstämma i Cell Impact AB

Extra bolagstämma i Cell Impact AB (Nasdaq First North GM: CI B) hölls den 9 augusti 2021.


Extraordinary general meeting of Cell Impact AB

An extraordinary general meeting of Cell Impact AB (Nasdaq First North GM: CI B) was held on August 9, 2021.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted